C2 Therapeutics, a Redwood City, CA firm, obtained the European CE Mark of approval for its Coldplay CryoBalloon Focal ablation system to be used for cold-blooded killing of pre-neoplastic tissue of Barrett’s Esophagus. The disease is often a precursor to esophageal cancer, but removing offending tissue precisely without damaging the healthy stuff around has remained a challenging proposition. The CryoBaloon Focal features a self-sizing balloon that simply inflates and automatically grabs onto the lumen wall. The physician can then direct the refrigerant to strike a specific region of the balloon, causing the cells nearby to freeze and die.
Since sizing of the balloon is no longer necessary and the procedure allows visualization of the esophagus during treatment, the company promises quick turnaround times and the associated cost savings when treating Barrett’s Esophagus.
Product page: Coldplay Focal…
Source: C2 Therapeutics…